Low-dose oral methotrexate for maintaining Crohn's disease remission: Where we stand

Journal of Clinical Gastroenterology

Volumn 39, Issue 9, 2005, Pages 751-756

  Sun, John H ^a   Das, Kiron M ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Crohn's disease; Oral methotrexate

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; FOLIC ACID; MERCAPTOPURINE; METHOTREXATE; PHOSPHORIBOSYLAMINOIMIDAZOLECARBOXAMIDE FORMYLTRANSFERASE; PLACEBO; PREDNISONE;

ANTIINFLAMMATORY ACTIVITY; CHRONIC DISEASE; CROHN DISEASE; DISEASE ACTIVITY; DRUG ABSORPTION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; IMMUNOMODULATION; LOW DRUG DOSE; PRIORITY JOURNAL; PSORIASIS; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CROHN DISEASE; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL ABSORPTION; METHOTREXATE; RANDOMIZED CONTROLLED TRIALS; REMISSION INDUCTION;

EID: 25444496170     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000177249.46130.a3     Document Type: Review

References (41)

1. Munkliolm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut. 1994;35:360-362.
2. Candy S, Wright J, Gerber M, et al. A controlled double-blind study of azathioprine in the management of Crohn's disease. Gut. 1995;37:674-678.
3. Glazier KD, Palance AL, Griffel LH, et al. The ten-year single-center experience with 6-mcrcaptopurinc in the treatment of inflammatory bowel disease. J Clin Gastroenteroll. 2005;39:21-26.
4. Pearson DC, May GR, Pick GH, et al. Azathioprine and 6-mercaptopurine in Crohn's disease: a meta-analysis. Ann Intern Med. 1995;122:132-142.
5. O'Donoghue DP, Dawaon AM, Powell-Tuck J, et al. Double-blinded withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet. 1978;2:955-957.
6. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut. 1995;37:674-678.
7. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT 1 randomised trial. Lancet. 2002;359:1541-1549.
8. Oliver S, Jurgen S. Low dose methotrexate in inflammatory bowel disease: current status and future directions. Am J Gastroenterol. 2003;98:530-537.
9. Lemann M, Zenjari T, Bouhnik Y. Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am J Gastroenterol. 2000;95:1730-1734.
10. Te HS, Schiano TD, Kuan SF, et al. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol. 2000;95:3150-3156.
11. Maetzel A, Bombardier C, Strand V, et al. How Canadian and US rheumatologists treat moderate and aggressive rheumatoid arthritis: a survey. J Rheumatol. 1998;25:2331-2338.
12. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum. 2002;46:328-346.
13. Schnabel A, Gross WL. Low dose methotrexate in rheumatic disease: efficacy, side effects, and risk factors for side effects. Semin Arthritis Rheum. 1994;23:310-327.
14. Suarez AM, Belseck E, Shea B, et al. Methotrexate for treating rheumatoid arthritis [last amended 1997]. Cochrane Database Syst Rev. 2002;4:CD000357.
15. Bologna C, Viu P, Picot MC, et al. Long-term follow-up of 453 rheumatoid arthritis patients treated with methotrexate: an open, retrospective, observational study. Br J Rheumatol. 1997;36:535-540.
16. Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histologie remission in patients with refractory inflammatory bowel disease. Ann Intern Med. 1989;110:353-356.
17. Vandeputte L, D'Haens G, Rutgeerts P. Methotrexate in refractory Crohn's disease. Inflamm Bowel Dis. 1999;5:11-15.
18. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. N Engl J Med. 1995;332:292-297.
19. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. N Engl J Med. 2000;342:1627-1632.
20. Balis FM, Mirro J, Reaman GH, et al. Pharmacokinetics of subcutaneous methotrexate. J Clin Oncol. 1988;6:1882-1886.
21. Brooks PJ, Spruill WJ, Parish RC, et al. Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis. Arthritis Rheum. 1990;33:91-94.
22. Mack DR, Young R, Kaufman SS, et al. Methotrexate in patients with Crohn's disease after 6-mercaptopurine. J Pediatr. 1998;132:830-835.
23. Kirn TF. Methotrexate shortage expected to last for months. Rheumatol News. 2005;4:1-2.
24. Bagott JE, Vaughan WH, Hudson BB. Inhibition of 5-aminoimidazole-4- carboxamide ribotide transformylase, adenosine deaminase and 5'adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem J. 1986;236:193-200.
25. Cronstein BN, Naime D, Ostad E. The anti-inflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminished leukocyte accumulation in an vivo model of inflammation. J Clin Invest. 1993;92:2675-2682.
26. Cronstein BN. Molecular therapeutics: methotrexate and its mechanism of action. Arthritis Rheum. 1996;39:1951-1960.
27. Genestier L, Paillot R, Fournel S, et al. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest. 1998;102:322-328.
28. Sierra EE, Goldman ID. Recent advances in the understanding of mechanism of membrane transporter of folate and antifolates. Semin Oncol. 1999;26:11-23.
29. Weitman SD, Weinberg AG, Coney LR, et al. Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. Cancer Res. 1992;52:6708-6711.
30. Oguey D, Kolliker F, Gerber NJ, et al. Effect of food on bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 1992;35:611-614.
31. Jundt JW, Browne BA, Fiocco GP, et al. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol. 1993;20:1845-1849.
32. Hamilton RA, Kremer JM. Why intramuscular methotrexate works better than oral drug in patients with rheumatoid arthritis. Br J Rheumatol. 1995;36:86-90.
33. Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose MTZ in rheumatoid arthritis. N Engl J Med. 1985;312:818-822.
34. Moshkowitz M, Oren R, Tishler M, et al. The absorption of low-dose methotrexate in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 1997;11:569-573.
35. Kurnik D, Loebstein R, Fishbein E, et al. Bioavailability of oral vs. subcutaneous methotrexate in patients with Crohn's disease. Aliment Pharmacol Ther. 2003;18:57-63.
36. Kozarek RA, Patterson DJ, Ball TJ, et al. Dose oral methotrexate (MTX) therapy maintain clinical remission in inflammatory bowel disease (IBD)? Gastroenterology. 1989;96:A272.
37. Baron TH, Truss CD, Elson CO. Low-dose oral methotrexate in refractory inflammatory bowel disease. Dig Dis Sci. 1993;38:1851-1856.
38. Chamiot-Prieur C, Lemann M, Mesnard B, et al. Treatment of refractory Crohn's disease (CD) with methotrexate. Gastroenterology. 1993;104:A680.
39. Oren R, Moshkowitz M, Odes S, et al. Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. Am J Castroenterol. 1997;92:2203-2209.
40. Arora S, Katkov W, Cooley J, et al. Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology. 1999;46:1724-1729.
41. Ardizzone S, Bollani S, Manzionna G, et al. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomized, investigator-blind study. Dig Liver Dis. 2003;35:619-627.